| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cesarean Section | 26 | 2023 | 55 | 6.060 |
Why?
|
| Pregnancy | 67 | 2024 | 1219 | 3.460 |
Why?
|
| Delivery, Obstetric | 14 | 2024 | 39 | 2.380 |
Why?
|
| Labor, Induced | 8 | 2023 | 19 | 2.360 |
Why?
|
| Gestational Age | 21 | 2020 | 146 | 2.260 |
Why?
|
| Parity | 8 | 2021 | 50 | 1.690 |
Why?
|
| Premature Birth | 9 | 2021 | 57 | 1.680 |
Why?
|
| Obstetric Labor Complications | 6 | 2024 | 18 | 1.490 |
Why?
|
| Labor, Obstetric | 3 | 2023 | 11 | 1.490 |
Why?
|
| Female | 75 | 2024 | 15472 | 1.490 |
Why?
|
| Hospitals | 8 | 2021 | 77 | 1.440 |
Why?
|
| Term Birth | 4 | 2021 | 10 | 1.440 |
Why?
|
| Retrospective Studies | 32 | 2024 | 2612 | 1.320 |
Why?
|
| Pregnancy Outcome | 15 | 2024 | 131 | 1.240 |
Why?
|
| Humans | 82 | 2025 | 28585 | 1.240 |
Why?
|
| Vaginal Birth after Cesarean | 3 | 2018 | 4 | 1.230 |
Why?
|
| Adult | 47 | 2024 | 7922 | 1.170 |
Why?
|
| Abortion, Induced | 3 | 2017 | 22 | 1.110 |
Why?
|
| Stillbirth | 4 | 2016 | 15 | 1.100 |
Why?
|
| Pregnancy Complications | 7 | 2024 | 111 | 1.080 |
Why?
|
| Patient Readmission | 5 | 2024 | 107 | 1.040 |
Why?
|
| Infant, Newborn | 21 | 2024 | 899 | 1.020 |
Why?
|
| Cost-Benefit Analysis | 9 | 2018 | 114 | 0.940 |
Why?
|
| United States | 22 | 2021 | 2201 | 0.930 |
Why?
|
| Ultrasonography, Prenatal | 7 | 2020 | 36 | 0.910 |
Why?
|
| Pandemics | 4 | 2025 | 196 | 0.860 |
Why?
|
| Pregnancy in Diabetics | 2 | 2021 | 21 | 0.850 |
Why?
|
| Logistic Models | 11 | 2024 | 409 | 0.840 |
Why?
|
| Pregnancy, Twin | 3 | 2018 | 6 | 0.830 |
Why?
|
| Diabetes, Gestational | 2 | 2021 | 68 | 0.790 |
Why?
|
| Trial of Labor | 3 | 2021 | 3 | 0.780 |
Why?
|
| Pregnancy, High-Risk | 2 | 2020 | 6 | 0.780 |
Why?
|
| Maternal Serum Screening Tests | 4 | 2018 | 4 | 0.740 |
Why?
|
| Health Services Research | 2 | 2020 | 43 | 0.730 |
Why?
|
| Perineum | 2 | 2018 | 14 | 0.720 |
Why?
|
| Decision Support Techniques | 7 | 2017 | 50 | 0.720 |
Why?
|
| Environment | 1 | 2021 | 65 | 0.700 |
Why?
|
| Oxytocin | 1 | 2021 | 6 | 0.700 |
Why?
|
| Oxytocics | 1 | 2021 | 5 | 0.700 |
Why?
|
| Catheterization | 1 | 2021 | 50 | 0.690 |
Why?
|
| Aneuploidy | 3 | 2017 | 21 | 0.680 |
Why?
|
| Risk Adjustment | 2 | 2017 | 8 | 0.670 |
Why?
|
| Postpartum Period | 6 | 2024 | 72 | 0.670 |
Why?
|
| Research Design | 2 | 2020 | 185 | 0.670 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 65 | 0.640 |
Why?
|
| Birth Weight | 6 | 2020 | 63 | 0.630 |
Why?
|
| Labor Onset | 1 | 2019 | 1 | 0.600 |
Why?
|
| Labor Stage, First | 1 | 2019 | 1 | 0.600 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 14 | 0.600 |
Why?
|
| Chorioamnionitis | 1 | 2018 | 4 | 0.590 |
Why?
|
| Lacerations | 1 | 2018 | 8 | 0.590 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 16 | 0.580 |
Why?
|
| Curriculum | 1 | 2020 | 296 | 0.570 |
Why?
|
| Maternal Age | 3 | 2020 | 25 | 0.540 |
Why?
|
| Labor Stage, Second | 3 | 2024 | 4 | 0.530 |
Why?
|
| Boston | 4 | 2021 | 7 | 0.500 |
Why?
|
| Prenatal Diagnosis | 4 | 2016 | 17 | 0.500 |
Why?
|
| Young Adult | 15 | 2021 | 2804 | 0.490 |
Why?
|
| Cohort Studies | 11 | 2024 | 893 | 0.480 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2015 | 18 | 0.480 |
Why?
|
| Maternal Health Services | 3 | 2020 | 9 | 0.460 |
Why?
|
| Risk Factors | 14 | 2018 | 2111 | 0.450 |
Why?
|
| Obstetrics | 2 | 2016 | 51 | 0.450 |
Why?
|
| Genetic Testing | 3 | 2016 | 68 | 0.450 |
Why?
|
| Placenta Previa | 4 | 2017 | 5 | 0.440 |
Why?
|
| Patient Safety | 1 | 2014 | 38 | 0.440 |
Why?
|
| Workload | 1 | 2014 | 43 | 0.430 |
Why?
|
| Time Factors | 6 | 2021 | 1600 | 0.410 |
Why?
|
| Risk Assessment | 6 | 2024 | 622 | 0.410 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 302 | 0.390 |
Why?
|
| Placenta Accreta | 4 | 2017 | 8 | 0.390 |
Why?
|
| Healthcare Disparities | 3 | 2020 | 93 | 0.380 |
Why?
|
| Fetal Weight | 1 | 2012 | 8 | 0.380 |
Why?
|
| Insurance, Health | 3 | 2020 | 51 | 0.370 |
Why?
|
| Fertilization in Vitro | 2 | 2015 | 24 | 0.360 |
Why?
|
| Patient Selection | 3 | 2017 | 149 | 0.360 |
Why?
|
| Qualitative Research | 2 | 2024 | 200 | 0.360 |
Why?
|
| Prenatal Care | 7 | 2020 | 41 | 0.340 |
Why?
|
| Herpes Genitalis | 2 | 2011 | 2 | 0.330 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2010 | 2 | 0.320 |
Why?
|
| Growth Charts | 2 | 2020 | 3 | 0.320 |
Why?
|
| Cervical Ripening | 2 | 2021 | 6 | 0.320 |
Why?
|
| Fetal Development | 2 | 2020 | 25 | 0.320 |
Why?
|
| Uterine Rupture | 2 | 2021 | 2 | 0.310 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2011 | 47 | 0.310 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 226 | 0.310 |
Why?
|
| Postnatal Care | 4 | 2024 | 18 | 0.310 |
Why?
|
| Adolescent | 8 | 2021 | 3165 | 0.310 |
Why?
|
| Health Care Costs | 2 | 2006 | 50 | 0.300 |
Why?
|
| Comorbidity | 3 | 2018 | 259 | 0.280 |
Why?
|
| Pre-Eclampsia | 3 | 2015 | 49 | 0.280 |
Why?
|
| Odds Ratio | 3 | 2017 | 236 | 0.260 |
Why?
|
| Hysterectomy | 5 | 2017 | 86 | 0.260 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 988 | 0.260 |
Why?
|
| Middle Aged | 14 | 2021 | 7310 | 0.260 |
Why?
|
| Down Syndrome | 2 | 2017 | 19 | 0.250 |
Why?
|
| Embryo Transfer | 1 | 2006 | 13 | 0.250 |
Why?
|
| Pregnancy Rate | 1 | 2006 | 49 | 0.250 |
Why?
|
| Quality of Health Care | 2 | 2018 | 83 | 0.240 |
Why?
|
| Acyclovir | 1 | 2005 | 8 | 0.240 |
Why?
|
| Military Personnel | 4 | 2020 | 49 | 0.230 |
Why?
|
| Pregnancy Trimester, First | 2 | 2016 | 14 | 0.230 |
Why?
|
| Child | 3 | 2021 | 2271 | 0.230 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2025 | 21 | 0.230 |
Why?
|
| Myocardial Infarction | 2 | 2008 | 351 | 0.220 |
Why?
|
| Evolution, Molecular | 1 | 2025 | 85 | 0.220 |
Why?
|
| DNA | 2 | 2016 | 375 | 0.210 |
Why?
|
| Prospective Studies | 4 | 2021 | 1272 | 0.210 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 116 | 0.210 |
Why?
|
| Hydrocephalus | 1 | 2024 | 55 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 164 | 0.210 |
Why?
|
| Quality-Adjusted Life Years | 5 | 2014 | 18 | 0.210 |
Why?
|
| Placenta | 2 | 2021 | 78 | 0.200 |
Why?
|
| Biomedical Technology | 1 | 2003 | 10 | 0.200 |
Why?
|
| Medically Uninsured | 1 | 2003 | 31 | 0.200 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2014 | 44 | 0.200 |
Why?
|
| Cataract Extraction | 1 | 2003 | 29 | 0.200 |
Why?
|
| Databases, Factual | 4 | 2019 | 265 | 0.200 |
Why?
|
| Depressive Disorder | 1 | 2003 | 56 | 0.200 |
Why?
|
| Morbidity | 5 | 2021 | 58 | 0.190 |
Why?
|
| Phenotype | 1 | 2025 | 682 | 0.190 |
Why?
|
| Puerperal Disorders | 2 | 2024 | 14 | 0.180 |
Why?
|
| NADPH Oxidase 2 | 1 | 2021 | 6 | 0.180 |
Why?
|
| Labor Presentation | 2 | 2018 | 3 | 0.180 |
Why?
|
| Weightlessness | 1 | 2021 | 5 | 0.170 |
Why?
|
| Hysterotomy | 1 | 2021 | 1 | 0.170 |
Why?
|
| Muscular Atrophy | 1 | 2021 | 32 | 0.170 |
Why?
|
| Catheters | 1 | 2021 | 24 | 0.170 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 51 | 0.170 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 480 | 0.170 |
Why?
|
| Chromosome Aberrations | 2 | 2018 | 37 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 63 | 0.170 |
Why?
|
| Infant, Small for Gestational Age | 3 | 2020 | 12 | 0.170 |
Why?
|
| Group Processes | 1 | 2020 | 8 | 0.170 |
Why?
|
| Geography | 1 | 2020 | 50 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2020 | 7 | 0.170 |
Why?
|
| Stress, Physiological | 1 | 2021 | 96 | 0.160 |
Why?
|
| Linear Models | 2 | 2017 | 202 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 302 | 0.160 |
Why?
|
| Focus Groups | 1 | 2020 | 101 | 0.160 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2011 | 5 | 0.160 |
Why?
|
| Regional Health Planning | 1 | 2019 | 3 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 251 | 0.150 |
Why?
|
| Insulin | 1 | 2021 | 324 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 2 | 2011 | 67 | 0.150 |
Why?
|
| Extraction, Obstetrical | 1 | 2018 | 1 | 0.150 |
Why?
|
| Episiotomy | 1 | 2018 | 2 | 0.150 |
Why?
|
| Fetal Death | 2 | 2015 | 21 | 0.150 |
Why?
|
| Narcotics | 1 | 2018 | 11 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 194 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2020 | 405 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 118 | 0.140 |
Why?
|
| Alleles | 1 | 2019 | 354 | 0.140 |
Why?
|
| Laparoscopy | 2 | 2017 | 156 | 0.140 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2018 | 4 | 0.140 |
Why?
|
| Monte Carlo Method | 3 | 2010 | 62 | 0.140 |
Why?
|
| Uterine Hemorrhage | 1 | 2018 | 9 | 0.140 |
Why?
|
| Genetic Counseling | 2 | 2016 | 14 | 0.140 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 16 | 0.140 |
Why?
|
| Biomarkers | 3 | 2021 | 770 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2017 | 10 | 0.140 |
Why?
|
| Commerce | 1 | 2018 | 54 | 0.140 |
Why?
|
| Head | 1 | 2017 | 19 | 0.140 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 8 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2018 | 172 | 0.130 |
Why?
|
| Hypertension | 1 | 2020 | 309 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2018 | 123 | 0.130 |
Why?
|
| Parturition | 1 | 2017 | 17 | 0.130 |
Why?
|
| Fetal Diseases | 1 | 2017 | 18 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 1026 | 0.130 |
Why?
|
| Postpartum Hemorrhage | 1 | 2017 | 10 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 38 | 0.130 |
Why?
|
| Pregnancy, Ectopic | 1 | 2016 | 11 | 0.130 |
Why?
|
| Incidence | 2 | 2018 | 568 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 77 | 0.120 |
Why?
|
| Chromosome Disorders | 1 | 2016 | 5 | 0.120 |
Why?
|
| Cordocentesis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2020 | 2402 | 0.120 |
Why?
|
| Trisomy | 1 | 2016 | 19 | 0.120 |
Why?
|
| Karyotyping | 1 | 2016 | 25 | 0.120 |
Why?
|
| Birth Injuries | 1 | 2016 | 2 | 0.120 |
Why?
|
| Brachial Plexus | 1 | 2016 | 6 | 0.120 |
Why?
|
| Home Childbirth | 1 | 2015 | 1 | 0.120 |
Why?
|
| Choice Behavior | 1 | 2016 | 28 | 0.120 |
Why?
|
| Women's Health | 1 | 2016 | 61 | 0.120 |
Why?
|
| Malpractice | 1 | 2015 | 7 | 0.120 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2015 | 6 | 0.120 |
Why?
|
| Appointments and Schedules | 1 | 2015 | 8 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 7 | 0.120 |
Why?
|
| Pregnancy in Adolescence | 1 | 2016 | 32 | 0.120 |
Why?
|
| Physicians | 1 | 2016 | 83 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 9 | 0.120 |
Why?
|
| Terminal Care | 1 | 2015 | 43 | 0.120 |
Why?
|
| Pregnancy Proteins | 1 | 2015 | 9 | 0.110 |
Why?
|
| Medicare | 1 | 2015 | 126 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 149 | 0.110 |
Why?
|
| Male | 8 | 2021 | 13772 | 0.110 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2014 | 1 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 472 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2014 | 68 | 0.110 |
Why?
|
| Exercise | 1 | 2019 | 493 | 0.110 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2014 | 16 | 0.110 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2014 | 4 | 0.110 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2014 | 8 | 0.110 |
Why?
|
| Neovascularization, Physiologic | 1 | 2015 | 124 | 0.110 |
Why?
|
| Cefazolin | 1 | 2013 | 6 | 0.110 |
Why?
|
| Ampicillin | 1 | 2013 | 14 | 0.100 |
Why?
|
| Fetal Growth Retardation | 1 | 2014 | 32 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 301 | 0.100 |
Why?
|
| Mass Screening | 2 | 2011 | 156 | 0.100 |
Why?
|
| Vaccination | 1 | 2014 | 192 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2011 | 17 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2011 | 20 | 0.090 |
Why?
|
| Maternal Mortality | 1 | 2011 | 10 | 0.090 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2010 | 1 | 0.080 |
Why?
|
| Genetic Carrier Screening | 1 | 2010 | 10 | 0.080 |
Why?
|
| Kenya | 2 | 2020 | 34 | 0.080 |
Why?
|
| Emigrants and Immigrants | 1 | 2010 | 22 | 0.080 |
Why?
|
| Contraception | 1 | 2010 | 29 | 0.080 |
Why?
|
| Medicaid | 1 | 2010 | 55 | 0.080 |
Why?
|
| Infant | 3 | 2021 | 1019 | 0.080 |
Why?
|
| Health Policy | 2 | 2015 | 61 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 534 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2013 | 631 | 0.070 |
Why?
|
| Mutation | 2 | 2025 | 864 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 671 | 0.070 |
Why?
|
| Ion Channels | 1 | 2008 | 28 | 0.070 |
Why?
|
| Oxygen Consumption | 2 | 2008 | 181 | 0.070 |
Why?
|
| New York | 2 | 2018 | 17 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 80 | 0.070 |
Why?
|
| Florida | 2 | 2018 | 55 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2007 | 53 | 0.070 |
Why?
|
| California | 2 | 2018 | 70 | 0.070 |
Why?
|
| Animals | 6 | 2025 | 10583 | 0.060 |
Why?
|
| Multiple Birth Offspring | 1 | 2006 | 1 | 0.060 |
Why?
|
| Pregnancy, Multiple | 1 | 2006 | 8 | 0.060 |
Why?
|
| Markov Chains | 1 | 2006 | 16 | 0.060 |
Why?
|
| Cerebral Palsy | 1 | 2006 | 30 | 0.060 |
Why?
|
| Infant, Premature | 2 | 2020 | 144 | 0.060 |
Why?
|
| Cost Savings | 1 | 2005 | 19 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 391 | 0.060 |
Why?
|
| Viral Tropism | 1 | 2025 | 6 | 0.060 |
Why?
|
| Cardiotocography | 1 | 2024 | 1 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2020 | 241 | 0.060 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2024 | 19 | 0.050 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 8 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 426 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 994 | 0.050 |
Why?
|
| Blood Transfusion | 2 | 2017 | 77 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 160 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2002 | 26 | 0.050 |
Why?
|
| Hospitalization | 2 | 2015 | 199 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 1983 | 164 | 0.050 |
Why?
|
| Rats | 2 | 2021 | 1587 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 47 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2002 | 52 | 0.050 |
Why?
|
| Heart | 1 | 1983 | 224 | 0.050 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2021 | 3 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2021 | 15 | 0.040 |
Why?
|
| Anthropometry | 1 | 2020 | 93 | 0.040 |
Why?
|
| London | 1 | 2020 | 10 | 0.040 |
Why?
|
| Multiprotein Complexes | 1 | 2021 | 54 | 0.040 |
Why?
|
| Fetus | 1 | 2020 | 79 | 0.040 |
Why?
|
| Aged | 4 | 2016 | 5525 | 0.040 |
Why?
|
| Pan troglodytes | 1 | 2019 | 13 | 0.040 |
Why?
|
| Neanderthals | 1 | 2019 | 5 | 0.040 |
Why?
|
| Fetal Monitoring | 1 | 2019 | 1 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 75 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 664 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 421 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2019 | 72 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 244 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2019 | 185 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 209 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 468 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2018 | 30 | 0.040 |
Why?
|
| Health Personnel | 1 | 2019 | 96 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 72 | 0.030 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2017 | 6 | 0.030 |
Why?
|
| Maternal Health | 1 | 2017 | 4 | 0.030 |
Why?
|
| Coronary Circulation | 3 | 2008 | 30 | 0.030 |
Why?
|
| Diagnosis-Related Groups | 1 | 2017 | 10 | 0.030 |
Why?
|
| Military Family | 1 | 2017 | 1 | 0.030 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2017 | 4 | 0.030 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2017 | 15 | 0.030 |
Why?
|
| Uterine Artery Embolization | 1 | 2017 | 2 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2017 | 31 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 325 | 0.030 |
Why?
|
| Laparotomy | 1 | 2016 | 35 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 550 | 0.030 |
Why?
|
| Safety | 1 | 2016 | 32 | 0.030 |
Why?
|
| Travel | 1 | 2016 | 12 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2021 | 671 | 0.030 |
Why?
|
| Trisomy 13 Syndrome | 1 | 2016 | 1 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Trisomy 18 Syndrome | 1 | 2016 | 2 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2016 | 13 | 0.030 |
Why?
|
| Rh Isoimmunization | 1 | 2016 | 1 | 0.030 |
Why?
|
| Global Health | 1 | 2016 | 54 | 0.030 |
Why?
|
| Hydrops Fetalis | 1 | 2016 | 5 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 16 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2016 | 21 | 0.030 |
Why?
|
| Mitochondria, Heart | 2 | 2008 | 25 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 24 | 0.030 |
Why?
|
| Perfusion | 2 | 2008 | 43 | 0.030 |
Why?
|
| Gynecology | 1 | 2016 | 60 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2015 | 19 | 0.030 |
Why?
|
| Massachusetts | 1 | 2015 | 17 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 79 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 242 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 32 | 0.030 |
Why?
|
| Placenta Growth Factor | 1 | 2015 | 6 | 0.030 |
Why?
|
| Mice | 1 | 2025 | 4735 | 0.030 |
Why?
|
| African Americans | 1 | 2017 | 352 | 0.030 |
Why?
|
| Decision Making | 1 | 2015 | 177 | 0.030 |
Why?
|
| Rwanda | 1 | 2013 | 7 | 0.030 |
Why?
|
| Fever | 1 | 2013 | 31 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 38 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 732 | 0.020 |
Why?
|
| Infant, Premature, Diseases | 1 | 2012 | 37 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2011 | 13 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 60 | 0.020 |
Why?
|
| Women | 1 | 2011 | 12 | 0.020 |
Why?
|
| Cesarean Section, Repeat | 1 | 2011 | 1 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 240 | 0.020 |
Why?
|
| Fetal Organ Maturity | 1 | 2010 | 4 | 0.020 |
Why?
|
| Amniocentesis | 1 | 2010 | 3 | 0.020 |
Why?
|
| Adenosine Diphosphate | 2 | 2008 | 27 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2011 | 114 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2010 | 15 | 0.020 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2010 | 11 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 75 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 72 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2007 | 2045 | 0.020 |
Why?
|
| Family Planning Services | 1 | 2010 | 13 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 461 | 0.020 |
Why?
|
| Cell Respiration | 1 | 2008 | 9 | 0.020 |
Why?
|
| Uncoupling Protein 1 | 1 | 2008 | 14 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2008 | 36 | 0.020 |
Why?
|
| Citrate (si)-Synthase | 1 | 2008 | 23 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2008 | 153 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 46 | 0.020 |
Why?
|
| Physical Examination | 1 | 2007 | 53 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 288 | 0.020 |
Why?
|
| Heart Failure | 1 | 2008 | 250 | 0.010 |
Why?
|
| Adenine Nucleotides | 1 | 1984 | 2 | 0.010 |
Why?
|
| Methods | 1 | 1983 | 27 | 0.010 |
Why?
|
| Tritium | 1 | 1983 | 17 | 0.010 |
Why?
|
| Desipramine | 1 | 1983 | 4 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1983 | 36 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1983 | 35 | 0.010 |
Why?
|
| Plasma | 1 | 1983 | 32 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1984 | 120 | 0.010 |
Why?
|
| NAD | 1 | 1984 | 104 | 0.010 |
Why?
|
| Rabbits | 1 | 1983 | 277 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2002 | 35 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 1167 | 0.010 |
Why?
|
| Endocardium | 1 | 1984 | 16 | 0.000 |
Why?
|
| Adenosine Monophosphate | 1 | 1984 | 21 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1984 | 121 | 0.000 |
Why?
|
| Dogs | 1 | 1984 | 510 | 0.000 |
Why?
|